General InformationTurn Biotechnologies is a San Francisco-based biotech company founded in 2018 with 51-200 employees developing epigenetic reprogramming therapies to reverse cellular aging.
Funding & FinancialsThe company has raised approximately $70-80 million across multiple rounds including a Series B, with backing from prominent longevity and biotech investors.
Leadership & TeamFounded by Vittorio Sebastiano, a stem cell and reprogramming expert, with a team of scientists focused on epigenetic and cellular biology research.
Recent ActivityTurn Biotechnologies has been advancing its lead programs in cellular reprogramming with a focus on moving toward clinical applications in age-related diseases and tissue regeneration.